Nutraveris

Category 'CLINICAL EVIDENCE'

Thursday, May 9, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

Propolis may have beneficial effects in type 2 diabetic patients. The aim of this meta-analysis was to examine the available scientific evidences in order to clarify the effects of propolis in these patients.

Propolis may improve glucose control in type 2 diabetic patients

Six randomized and controlled trials, for a total of 373 participants, have been analyzed by the authors. The results of the meta-analysis revealed significant reductions in fasting plasma glucose (-13.51 mg/dl; 95% CI: -24.98, -2.04) and hemoglobin A1C (HbA1c, -0.52%, 95% CI:-0.94, -0.10) concentrations following propolis supplementation. However, no significant effect on insulin concentration has been noted (-0.53 pmol/L, 95% CI: -1.69, 0.63) or insulin sensitivity (HOMA-IR, -0.543, 95% CI: -1.72, 0.64).

Therefore, these results suggest that propolis supplementation may be effective for the short-term (fasting blood glucose) and long-term (HbA1c) management of glucose control in type 2 diabetic patients.

 

Karimian J, Hadi A, Pourmasoumi M, Najafgholizadeh A, Ghavami A. The efficacy of propolis on markers of glycemic control in adults with type 2 diabetes mellitus: A systematic review and meta-analysis. Phytother Res. 2019 Apr 5.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, May 2, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

Vitamins B are frequently used to improve cognitive function, even if strong clinical evidences are lacking. The aim of this systematic review and meta-analysis was to examine the available data on vitamin B supplementation and cognitive functions in the elderly.

 

Vitamin B supplementation for cognitive function: lack of effect in the elderly.

The authors compiled 31 randomized and placebo-controlled study examining the effects of vitamins B (B6, B9 and/or B12) in older adults with or without cognitive impairment. 10 studies have been conducted in subjects with cognitive impairment (1925 participants, whereas 21 other studies have been conducted in healthy subjects (15,104 participants). All studies except two have failed to highlight any significant effects of vitamins B supplementations. No improvement in the Mini-mental State Examination (MMSE) score has been noted for subjects with or without cognitive impairment.

Therefore, it seems that, despite their recognition by EFSA as important for normal psychological function, vitamins B supplementations are not effective for improving cognitive functions in elderly with or without cognitive impairment.

Ford AH, Almeida OP. Effect of Vitamin B Supplementation on Cognitive Function in the Elderly: A Systematic Review and Meta-Analysis. Drugs Aging. 2019 Apr 4.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, April 25, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This pilot clinical study, aimed to determine the effects of daily supplementation during 6 months with 1×108 CFU of Lactobacillus salivarius PS7, selected for its antagonism of otophathogens, in the prevention of otitis in 61 children suffering of recurrent acute otitis media.

 

Supplementation with Lactobacillus salivarius prevents recurrent acute otitis in children.

Comparison between the number of AOM episodes reported during the 6 months of the probiotic treatment and those reported during the previous 6 months. **, statistically significant change (p < 0.05; ¬χ2 test).

Thirty six percent (36%) of the recruited children suffered at least one episode of acute otitis media, with a median duration of 4 days. In contrast, 70% of the children with recurrent acute otitis media who were attended by the same pediatrician in the same period but did not receive the probiotic strain suffered at least one acute otitis media episode with a median duration of 6 days. The number of acute otitis media episodes during the 6-month intervention period decreased by 84% when compared to the number registered in the 6 months that preceded the intervention (Figure 1). Moreover, the microbial density in the external auditory canal decreased notably along the intervention period, from >3.5 log10 CFU at the baseline (all the cultures were positive at this sampling time) to <2 log10 CFU at the end of the intervention (with 22% of the cultures being negative).

In conclusion, Lactobacillus salivarius PS7 is a promising strain for the prevention of recurrent acute otitis media in infants and children.

 

Cárdenas N, Martín V, Arroyo R, López M, Carrera M, Badiola C, Jiménez E, Rodríguez JM. Prevention of Recurrent Acute Otitis Media in Children Through the Use of Lactobacillus salivarius PS7, a Target-Specific Probiotic Strain. Nutrients. 2019 Feb 12;11(2).

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, April 18, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

The aim of this randomized, double-blind and placebo-controlled trial was to investigate the efficacy and safety of Nigella sativa seed oil in the treatment of patients with non-alcoholic fatty liver disease (NAFLD).

To do so, 120 patients with non-alcoholic fatty liver disease were randomized to receive either 2.5mL of a fully standardized N. sativa seed oil every 12h or a placebo for 3 months.

Beneficial effect of Nigella sativa supplementation on non-alcoholic fatty liver disease.

 

Results showed that grade of hepatic steatosis was significantly reduces in the oil group compared to the placebo (p = 0.004). Moreover, triglycerides, LDL-C and HDL-C were significantly decreased compared to placebo (p = 0.001, p = 0.01, p = 0.001 respectively). However, the oil did not significantly affect the other outcome variables compared to the placebo (all p > 0.05).

Authors concluded that Nigella sativa seed oil seems to be safe and improve liver disorders in the NAFLD patients.

 

Khonche A, Huseini HF, Gholamian M, Mohtashami R, Nabati F, Kianbakht S. Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial. J Ethnopharmacol. 2019 Apr 24;234:106-111.

 

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, April 11, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This randomized, single-blind, placebo-controlled study evaluated among 70 women with acute uncomplicated cystitis the effects of daily supplementation during 3 days with 2000 mg of spray-dried aqueous extract of green tea or placebo (Starch) along with antibiotherapy (trimethoprim-sulfamethoxazole).

 Green tea as adjunctive therapy for acute uncomplicated cystitis in women

Women in the green tea group showed a decrease in the prevalence of cystitis symptoms compared to baseline, from 68% to 61% after 1 day, to 34% after 2 days and to 2% after 3 days. This prevalence of cystitis symptoms decrease is significantly higher in the green tea group than in the placeob group at all measurement point (all p < 0.01). Also a significant improvement in urinalysis results (abnormal urine color, pyuria, bacteruria, all p < 0.0001) were noted in the green tea group compared to the placebo group after 3 days of supplementation.

 

Authors concluded that green tea extract is efficient as adjunctive therapy for the management of cystitis symptoms in women with acute uncomplicated cystitis.

 

Kheirabadi Z, Mehrabani M, Sarafzadeh F, Dabaghzadeh F, Ahmadinia N. Green tea as an adjunctive therapy for treatment of acute uncomplicated cystitis in women: A randomized clinical trial. Complementary Therapies in Clinical Practice 34 (2019) 13–16

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87